177 related articles for article (PubMed ID: 35216261)
1. Criticality of Surface Characteristics of Intravenous Iron-Carbohydrate Nanoparticle Complexes: Implications for Pharmacokinetics and Pharmacodynamics.
Funk F; Flühmann B; Barton AE
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216261
[TBL] [Abstract][Full Text] [Related]
2. Tissue biodistribution of intravenous iron-carbohydrate nanomedicines differs between preparations with varying physicochemical characteristics in an anemic rat model.
Funk F; Weber K; Nyffenegger N; Fuchs JA; Barton A
Eur J Pharm Biopharm; 2022 May; 174():56-76. PubMed ID: 35337966
[TBL] [Abstract][Full Text] [Related]
3. Iron Oxide Nanoparticle Formulations for Supplementation.
Pai AB
Met Ions Life Sci; 2019 Jan; 19():. PubMed ID: 30855107
[TBL] [Abstract][Full Text] [Related]
4. Factors influencing safety and efficacy of intravenous iron-carbohydrate nanomedicines: From production to clinical practice.
Nikravesh N; Borchard G; Hofmann H; Philipp E; Flühmann B; Wick P
Nanomedicine; 2020 Jun; 26():102178. PubMed ID: 32145382
[TBL] [Abstract][Full Text] [Related]
5. Putting square pegs in round holes: Why traditional pharmacokinetic principles cannot universally be applied to iron-carbohydrate complexes.
Alston AB; Digigow R; Flühmann B; Wacker MG
Eur J Pharm Biopharm; 2023 Jul; 188():6-14. PubMed ID: 37142131
[TBL] [Abstract][Full Text] [Related]
6. Snapshots of Iron Speciation: Tracking the Fate of Iron Nanoparticle Drugs via a Liquid Chromatography-Inductively Coupled Plasma-Mass Spectrometric Approach.
Neu HM; Alexishin SA; Brandis JEP; Williams AMC; Li W; Sun D; Zheng N; Jiang W; Zimrin A; Fink JC; Polli JE; Kane MA; Michel SLJ
Mol Pharm; 2019 Mar; 16(3):1272-1281. PubMed ID: 30676753
[TBL] [Abstract][Full Text] [Related]
7. Differences between intravenous iron products: focus on treatment of iron deficiency in chronic heart failure patients.
Martin-Malo A; Borchard G; Flühmann B; Mori C; Silverberg D; Jankowska EA
ESC Heart Fail; 2019 Apr; 6(2):241-253. PubMed ID: 30694615
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the Physicochemical Properties of the Iron Nanoparticle Drug Products: Brand and Generic Sodium Ferric Gluconate.
Brandis JEP; Kihn KC; Taraban MB; Schnorr J; Confer AM; Batelu S; Sun D; Rodriguez JD; Jiang W; Goldberg DP; Langguth P; Stemmler TL; Yu YB; Kane MA; Polli JE; Michel SLJ
Mol Pharm; 2021 Apr; 18(4):1544-1557. PubMed ID: 33621099
[TBL] [Abstract][Full Text] [Related]
9. Critical nanomaterial attributes of iron-carbohydrate nanoparticles: Leveraging orthogonal methods to resolve the 3-dimensional structure.
Krupnik L; Joshi P; Kappler A; Flühmann B; Alston AB; Digigow R; Wick P; Neels A
Eur J Pharm Sci; 2023 Sep; 188():106521. PubMed ID: 37423578
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo DFO-chelatable labile iron release profiles among commercially available intravenous iron nanoparticle formulations.
Pai AB; Pai MP; Meyer DE; Bales BC; Cotero VE; Zheng N; Jiang W
Regul Toxicol Pharmacol; 2018 Aug; 97():17-23. PubMed ID: 29857115
[TBL] [Abstract][Full Text] [Related]
11. Effects of ascorbic acid on interactions between ciprofloxacin and ferrous sulphate, sodium ferrous citrate or ferric pyrophosphate, in mice.
Motoya T; Miyashita M; Kawachi A; Yamada K
J Pharm Pharmacol; 2000 Apr; 52(4):397-401. PubMed ID: 10813549
[TBL] [Abstract][Full Text] [Related]
12. Complexity of intravenous iron nanoparticle formulations: implications for bioequivalence evaluation.
Pai AB
Ann N Y Acad Sci; 2017 Nov; 1407(1):17-25. PubMed ID: 29027212
[TBL] [Abstract][Full Text] [Related]
13. Core size determination and structural characterization of intravenous iron complexes by cryogenic transmission electron microscopy.
Wu Y; Petrochenko P; Chen L; Wong SY; Absar M; Choi S; Zheng J
Int J Pharm; 2016 May; 505(1-2):167-74. PubMed ID: 27001529
[TBL] [Abstract][Full Text] [Related]
14. ¹³C NMR spectroscopy as a tool for the in situ characterisation of iron-supplementing preparations.
Kästele X; Sturm C; Klüfers P
Eur J Pharm Biopharm; 2014 Apr; 86(3):469-77. PubMed ID: 24309008
[TBL] [Abstract][Full Text] [Related]
15. Uncovering the dynamics of cellular responses induced by iron-carbohydrate complexes in human macrophages using quantitative proteomics and phosphoproteomics.
Bossart J; Rippl A; Barton Alston AE; Flühmann B; Digigow R; Buljan M; Ayala-Nunez V; Wick P
Biomed Pharmacother; 2023 Oct; 166():115404. PubMed ID: 37657262
[TBL] [Abstract][Full Text] [Related]
16. An Analytical Method for Determination of Total Iron in Pharmaceuticalgrade Intravenous Iron Colloidal Complexes by Redox-Potentiometry.
Kamisetty MK; Medisetty R; Ramesh B; Pappureddy S; Kashanna J; Govinda V; Kishore R
Pharm Nanotechnol; 2023; 11(5):486-492. PubMed ID: 37151072
[TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetics and pharmacodynamics of iron preparations.
Geisser P; Burckhardt S
Pharmaceutics; 2011 Jan; 3(1):12-33. PubMed ID: 24310424
[TBL] [Abstract][Full Text] [Related]
18. Dynamic Light Scattering Analysis for the Determination of the Particle Size of Iron-Carbohydrate Complexes.
Burgert M; Marques CB; Borchard G; Philipp E; Wilhelm M; Alston A; Digigow R
J Vis Exp; 2023 Jul; (197):. PubMed ID: 37486118
[TBL] [Abstract][Full Text] [Related]
19. Controlled synthesis of iron oxyhydroxide (FeOOH) nanoparticles using secretory compounds from
Ghanbariasad A; Taghizadeh SM; Show PL; Nomanbhay S; Berenjian A; Ghasemi Y; Ebrahiminezhad A
Bioengineered; 2019 Dec; 10(1):390-396. PubMed ID: 31495263
[TBL] [Abstract][Full Text] [Related]
20. Bioavailability of trivalent iron in oral iron preparations. Therapeutic efficacy and iron absorption from simple ferric compounds and high- or low-molecular weight ferric hydroxide-carbohydrate complexes.
Heinrich HC
Arzneimittelforschung; 1975 Mar; 25(3):420-6. PubMed ID: 1174047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
